SkinnyRx vs MEDVi vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re cross-shopping SkinnyRx and MEDVi for cash-pay GLP-1 weight loss, you’re probably staring at two landing pages with similar promises and slightly different price tags — and neither one is giving you the full picture. SkinnyRx advertises semaglutide injectables from $199/mo with sublingual and tablet formats; MEDVi runs a $179 first-month, $299/mo thereafter pricing model with bundled 24/7 support. Both received FDA warning letters in February 2026 about marketing claims. Both are compounded-medication platforms. Both are cash-pay. The real questions a careful shopper should ask aren’t answered on either company’s homepage: what does month-12 actually cost, what oversight model do you get, and is anyone using your genetics to decide your dose? This article walks the three-way comparison — SkinnyRx vs MEDVi vs PlexusDx — on cost, formats, oversight, safety, and personalization, and shows where the PlexusDx Semaglutide Injection Protocol, Tirzepatide Injection Protocol, and Microdose GLP-1 Protocol sit relative to both competitors.

SkinnyRx vs MEDVi vs PlexusDx — quick decision frame

All three are cash-pay compounded GLP-1 platforms. SkinnyRx leans into format flexibility — semaglutide as injectable, tablet, or sublingual drops, plus tirzepatide as injectable or tablet — with free overnight shipping and a stated injectable price from $199/mo. MEDVi leads with a $179 first-month promotional price that resets to $299/mo from month two onward, bundled with 24/7 messaging and optional video consultations. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies across six protocols and four mechanism classes — the Microdose GLP-1 Protocol at $129/mo flat, Semaglutide Injection at $149/mo, Semaglutide Oral from $249/mo, Tirzepatide Injection at $249/mo, Tirzepatide Oral at $279/mo, and GLP-Squared dual-compound at $249/mo — paired with the optional Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) so dosing decisions are anchored to GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants rather than a population-average titration schedule. PlexusDx is cash-pay across all 50 states with no membership fee; five states require a scheduled live consult instead of async intake.

The real annual cost: SkinnyRx vs MEDVi vs PlexusDx

Year-one math is where the three providers separate cleanly. SkinnyRx semaglutide injectable at $199/mo runs roughly $2,388/year if pricing holds steady. MEDVi semaglutide injectable at $179 month one + $299 × 11 months totals $3,468/year — the gap between MEDVi’s teaser price and the going rate is roughly $1,080 over twelve months. PlexusDx spans a much wider price band by design: Microdose GLP-1 Protocol at $129/mo flat works out to $1,548/year, Semaglutide Injection at $149/mo runs $2,148–$2,748/year, Tirzepatide Injection at $249/mo runs $2,748–$3,708/year, and GLP-Squared dual-compound at $249/mo runs $2,148–$3,900/year. Tirzepatide tells the same story: SkinnyRx lists tirzepatide injectable at $299/mo ($3,588/year), MEDVi at $349/mo ($4,188/year), and PlexusDx at $249/mo ($2,748–$3,708/year). On the lowest-cost tier, the PlexusDx Microdose protocol is more than $1,900/year cheaper than MEDVi’s steady-state semaglutide injectable price. Add $99 for the Precision Peptide Genetic Test as an add-on after month one and the genetic-baseline-included totals stay competitive with both rivals.

Formats: how many ways can you actually take it?

SkinnyRx’s standout feature is format selection — semaglutide is offered as injectable, oral tablet, and sublingual drops; tirzepatide is offered as injectable or tablet. That gives needle-averse patients three semaglutide routes to consider. MEDVi offers semaglutide and tirzepatide in injectable and tablet form — two routes per drug, no sublingual option. PlexusDx covers more delivery permutations across six protocols: weekly semaglutide injection, weekly tirzepatide injection, daily oral semaglutide tablet, daily oral tirzepatide tablet, four-variant Microdose GLP-1 Protocol (capsule, troche, lozenge, sublingual), and the GLP-Squared dual-compound combining semaglutide and tirzepatide for advanced or escalation use. If you’re needle-averse, the PlexusDx Microdose troche, lozenge, or sublingual options sit alongside SkinnyRx’s sublingual drops as the broadest non-injection menu in this comparison. If you’re looking for a stacked sema + tirz approach, only PlexusDx publishes a formal dual-compound protocol — neither SkinnyRx nor MEDVi offers a built-in dual-compound option in this comparison.

Compounded vs FDA-approved — the medication source question

This is the substantive medication note that applies to all three providers. SkinnyRx, MEDVi, and PlexusDx all dispense compounded semaglutide and tirzepatide — pharmacy-prepared formulations of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products; they are prepared by licensed compounding pharmacies under U.S. compounding regulations. The FDA-approved finished products in the GLP-1 weight-loss class are Wegovy, Zepbound, Saxenda (semaglutide and tirzepatide–adjacent injectables), Rybelsus (oral semaglutide), Ozempic, Mounjaro, Trulicity, and Victoza — sold through retail and specialty pharmacies, not directly through any of the three providers in this comparison. If branded FDA-approved medication is a hard requirement, none of SkinnyRx, MEDVi, or PlexusDx is the right fit — you’d need to pursue Wegovy or Zepbound through a clinic that prescribes branded products and accepts insurance or self-pay programs like Lilly Direct. Both SkinnyRx and MEDVi received FDA warning letters on February 20, 2026 about marketing claims for compounded GLP-1 products; the letters cited misleading marketing rather than safety incidents, and both providers continued operating with licensed compounding pharmacies.

Safety, side effects, and clinical oversight

All three programs prescribe medications in the GLP-1 receptor agonist class (and tirzepatide, a GIP/GLP-1 dual agonist). The labeled side-effect profile is well-characterized across both compounds: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented; the boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies. The clinical-oversight model differs by platform. SkinnyRx routes through licensed providers and a customer-service team via app. MEDVi adds 24/7 clinical messaging and optional video consultations to the bundled price. PlexusDx routes through licensed U.S. compounding pharmacies and a clinical team that reviews the patient’s genetic results before titration when the Precision Peptide Genetic Test is included — a stratification step neither SkinnyRx nor MEDVi performs. None of the three accepts insurance; all three accept HSA/FSA cards subject to plan rules. Severe symptoms — difficulty breathing, severe abdominal pain, signs of allergic reaction — warrant a 911 call or ER visit, not a telehealth message, regardless of which platform you use.

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients, and the difference shows up in real-world tolerability and weight loss. Variants in GLP1R (the GLP-1 receptor itself), GIPR (the GIP receptor relevant to tirzepatide), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 unique genes and 57 genetic variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician knows whether a faster titration, a slower one, a tirzepatide-first approach, or the dual-compound GLP-Squared route is more likely to fit your biology before week one. Neither SkinnyRx nor MEDVi performs this step — both start from a population-average titration and adjust by subjective tolerability over the first 8–12 weeks. PlexusDx anchors the same conversation to a measurable genetic baseline, available standalone for $298 or as a $99 add-on after your first month on any protocol.

Cancellation, guarantees, and shipping — what each platform commits to

SkinnyRx publishes a refund policy that allows a full refund before the prescription is finalized, with cancellations required at least five days before a renewal processing date; the company markets a 10% body-weight-loss guarantee with terms attached. MEDVi requires 72 hours’ notice before a billing date and limits refunds once medication has been ordered to the pharmacy; MEDVi’s money-back guarantee applies after five months of documented adherence and deducts a 25% consultation fee. SkinnyRx ships free overnight on every order; MEDVi ships free with typical delivery in 2–5 business days. PlexusDx is cash-pay with no membership fee, ships compounded medications and supplies as part of the all-inclusive monthly price, and operates in all 50 states — with five states requiring a scheduled live consult rather than async intake. PlexusDx does not advertise a results-based money-back guarantee; protocol pricing is upfront and the genetic test add-on is opt-in.

Which one fits — a four-question decision frame

Question 1: Are you needle-averse and want the broadest non-injection menu in one place? SkinnyRx’s sublingual semaglutide and PlexusDx’s Microdose GLP-1 Protocol (capsule, troche, lozenge, sublingual) are the leading options — PlexusDx is cheaper at $129/mo flat. Question 2: Do you value 24/7 clinical messaging and bundled video consults enough to pay $299/mo from month two? MEDVi delivers that bundle. Question 3: Is your dominant decision factor cost over twelve months, with no insurance coverage? PlexusDx Microdose GLP-1 Protocol at $1,548/year and Semaglutide Injection at $2,148–$2,748/year are the most aggressive cash-pay tiers in this comparison. Question 4: Do you want a measurable genetic baseline informing dose selection and titration before your first injection? PlexusDx is the only option in this three-way comparison that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

Is SkinnyRx, MEDVi, or PlexusDx cheaper long-term?

For semaglutide injectable specifically, PlexusDx at $149/mo is the cheapest steady-state option in this three-way comparison, ahead of SkinnyRx at $199/mo and MEDVi at $299/mo from month two. Across twelve months, PlexusDx Microdose GLP-1 Protocol at $129/mo flat ($1,548/year) is the lowest total in the group.

Did the FDA warn SkinnyRx and MEDVi in 2026?

Yes. Both received warning letters on February 20, 2026 from the FDA’s Office of Compounding Quality and Compliance. The letters cited misleading marketing claims rather than product contamination, recalls, or safety emergencies. Both providers continued operating using licensed compounding pharmacies after the letters were issued.

Are SkinnyRx, MEDVi, and PlexusDx selling FDA-approved Wegovy or compounded semaglutide?

All three primarily sell compounded semaglutide and compounded tirzepatide, not FDA-approved branded finished products. Compounded GLP-1s are prepared by licensed compounding pharmacies and are not the same as Wegovy, Ozempic, Mounjaro, or Zepbound. If branded medication is a hard requirement, none of these three providers is the right fit.

Which one is best for someone scared of needles?

PlexusDx and SkinnyRx tie on non-injection breadth. PlexusDx’s Microdose GLP-1 Protocol at $129/mo flat ships in four variants — capsule, troche, lozenge, and sublingual — while SkinnyRx offers sublingual semaglutide drops alongside tablets. MEDVi offers tablets only on the non-injection side.

Can I use insurance with any of these three providers?

No. All three are cash-pay programs. SkinnyRx and MEDVi accept HSA and FSA cards subject to plan rules; PlexusDx is cash-pay across all 50 states with no membership fee. If your insurance covers Wegovy or Zepbound at a manageable copay, that route is typically cheapest and worth pursuing first.

Does PlexusDx offer a money-back guarantee like SkinnyRx and MEDVi?

PlexusDx does not advertise a results-based weight-loss guarantee. Protocol pricing is published upfront and the Precision Peptide Genetic Test is an opt-in $99 add-on after your first month or $298 standalone — the personalization framing replaces the percent-loss guarantee model used by SkinnyRx and MEDVi.

Does PlexusDx offer tirzepatide and dual-compound options?

Yes. PlexusDx offers Tirzepatide Injection at $249/mo, Tirzepatide Oral at $279/mo, and the GLP-Squared dual-compound semaglutide-plus-tirzepatide protocol at $249/mo. Neither SkinnyRx nor MEDVi publishes a formal dual-compound protocol in this comparison.

SkinnyRx vs MEDVi vs PlexusDx (2026): GLP-1 Pricing, Formats and Genetics | PlexusDx